SAN DIEGO, February 25, 2021 PRNewswire – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers [...]
SAN DIEGO, January 11, 2020 PRNewswire – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers [...]
SAN DIEGO, January 4, 2020 PRNewswire – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of [...]
SAN DIEGO, Nov. 25, 2020 PRNewswire – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers [...]
PR Newswire, San Diego – November 9, 2020 – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the [...]
PR Newswire, San Diego – October 5, 2020 – DDTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the [...]
PR Newswire, San Diego – September 28, 2020 – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the [...]
-CMT is a genetic rare disease driven by the duplication of the PMP22 gene- PR Newswire, San Diego – September 21, 2020 – DTx Pharma, Inc. [...]
DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that the company will [...]
DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the appointment of [...]